JP2017510567A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510567A5
JP2017510567A5 JP2016555690A JP2016555690A JP2017510567A5 JP 2017510567 A5 JP2017510567 A5 JP 2017510567A5 JP 2016555690 A JP2016555690 A JP 2016555690A JP 2016555690 A JP2016555690 A JP 2016555690A JP 2017510567 A5 JP2017510567 A5 JP 2017510567A5
Authority
JP
Japan
Prior art keywords
antibody
seq
mcam
amino acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016555690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051787 external-priority patent/WO2015136470A1/en
Publication of JP2017510567A publication Critical patent/JP2017510567A/ja
Publication of JP2017510567A5 publication Critical patent/JP2017510567A5/ja
Pending legal-status Critical Current

Links

JP2016555690A 2014-03-12 2015-03-12 抗ｍｃａｍ抗体および関連の使用方法 Pending JP2017510567A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461952116P 2014-03-12 2014-03-12
US61/952,116 2014-03-12
US201461952833P 2014-03-13 2014-03-13
US61/952,833 2014-03-13
US201462023724P 2014-07-11 2014-07-11
US62/023,724 2014-07-11
US201462068419P 2014-10-24 2014-10-24
US62/068,419 2014-10-24
PCT/IB2015/051787 WO2015136470A1 (en) 2014-03-12 2015-03-12 Anti-mcam antibodies and associated methods of use

Publications (2)

Publication Number Publication Date
JP2017510567A JP2017510567A (ja) 2017-04-13
JP2017510567A5 true JP2017510567A5 (enExample) 2018-03-29

Family

ID=52823724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555690A Pending JP2017510567A (ja) 2014-03-12 2015-03-12 抗ｍｃａｍ抗体および関連の使用方法

Country Status (18)

Country Link
US (1) US20150259419A1 (enExample)
EP (1) EP3116912A1 (enExample)
JP (1) JP2017510567A (enExample)
KR (1) KR20160131061A (enExample)
CN (1) CN106132990A (enExample)
AU (1) AU2015228454A1 (enExample)
BR (1) BR112016020871A2 (enExample)
CA (1) CA2942233A1 (enExample)
CL (1) CL2016002257A1 (enExample)
CU (1) CU20160133A7 (enExample)
EA (1) EA201691836A1 (enExample)
IL (1) IL247754A0 (enExample)
MX (1) MX2016011731A (enExample)
PE (1) PE20161210A1 (enExample)
PH (1) PH12016501760A1 (enExample)
SG (1) SG11201606274XA (enExample)
TW (1) TW201623331A (enExample)
WO (1) WO2015136470A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CA2998716A1 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CN110114078B (zh) 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
CN113474360B (zh) 2019-02-18 2025-01-07 伊莱利利公司 治疗性抗体制剂
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
CN121443743A (zh) 2023-05-23 2026-01-30 赛纳生物技术公司 串联融合剂和相关脂质颗粒
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN119192349A (zh) * 2024-07-18 2024-12-27 北京市延庆区疾病预防控制中心 用于检测黄连素抗性病毒的试剂及方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP2005514409A (ja) 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1382615A1 (en) * 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2574146C (en) * 2004-07-20 2015-06-30 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
BRPI0808542A2 (pt) 2007-03-02 2014-08-26 Boehringer Ingelheim Pharma Aperfeiçoamento de produção de proteína
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
IN2012DN02634A (enExample) * 2009-10-15 2015-09-04 Abbvie Inc
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
US20140314744A1 (en) * 2011-06-06 2014-10-23 Neotope Biosciences Limited Mcam antagonists and methods of treatment
WO2013083497A1 (en) * 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法

Similar Documents

Publication Publication Date Title
JP2017510567A5 (enExample)
US11091546B2 (en) Optimized PNE-based chimeric receptor T cell switches and uses thereof
CN107353342B (zh) PDGF受体β结合多肽
JP2017518258A5 (enExample)
KR102473544B1 (ko) 항체-fynomer 접합체
JP7460819B2 (ja) ヒト抗セマフォリン４ｄ抗体
JP2018521691A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2014221758A5 (enExample)
JP2018502060A5 (enExample)
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
WO2016191643A4 (en) Tigit-binding agents and uses thereof
JP2015535691A5 (enExample)
HRP20192285T1 (hr) Anti-ox40 protutijela i postupci uporabe
HK1254289A1 (zh) 调控免疫反应的方法及抗体
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
JP2020513809A5 (enExample)
JP2020513791A5 (enExample)
JP2019510739A5 (enExample)
WO2015057834A1 (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
JP2017523786A5 (enExample)
JP2016512551A5 (enExample)
HRP20200881T1 (hr) Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe
JP2008532949A (ja) ヒト化ｌ２４３抗体